IL297596A - Modulators of akt3 and methods of using them - Google Patents

Modulators of akt3 and methods of using them

Info

Publication number
IL297596A
IL297596A IL297596A IL29759622A IL297596A IL 297596 A IL297596 A IL 297596A IL 297596 A IL297596 A IL 297596A IL 29759622 A IL29759622 A IL 29759622A IL 297596 A IL297596 A IL 297596A
Authority
IL
Israel
Prior art keywords
alkyl
cycloalkyl
akt3
disease
aryl
Prior art date
Application number
IL297596A
Other languages
English (en)
Hebrew (he)
Original Assignee
Georgiamune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgiamune Llc filed Critical Georgiamune Llc
Publication of IL297596A publication Critical patent/IL297596A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Amplitude Modulation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL297596A 2020-05-08 2021-05-07 Modulators of akt3 and methods of using them IL297596A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063021797P 2020-05-08 2020-05-08
PCT/US2021/031372 WO2021226510A2 (en) 2020-05-08 2021-05-07 Akt3 modulators and methods of use thereof

Publications (1)

Publication Number Publication Date
IL297596A true IL297596A (en) 2022-12-01

Family

ID=78468492

Family Applications (1)

Application Number Title Priority Date Filing Date
IL297596A IL297596A (en) 2020-05-08 2021-05-07 Modulators of akt3 and methods of using them

Country Status (12)

Country Link
US (1) US20230181563A1 (https=)
EP (1) EP4146196A4 (https=)
JP (1) JP2023525758A (https=)
KR (1) KR20230019109A (https=)
CN (1) CN115956078A (https=)
AU (1) AU2021269065A1 (https=)
BR (1) BR112022022327A2 (https=)
CA (1) CA3182675A1 (https=)
IL (1) IL297596A (https=)
MX (1) MX2022014019A (https=)
PH (1) PH12022553026A1 (https=)
WO (1) WO2021226510A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023525757A (ja) * 2020-05-08 2023-06-19 ジョージアミューン・インコーポレイテッド Ａｋｔ３モジュレーター
AU2021266786A1 (en) * 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4993838B2 (ja) * 2000-08-11 2012-08-08 バーテックス ファーマシューティカルズ インコーポレイテッド Ｐ３８のインヒビターとしてのピリジン誘導体
ATE461179T1 (de) * 2003-04-24 2010-04-15 Merck Sharp & Dohme Hemmer der akt aktivität
WO2008046085A2 (en) * 2006-10-12 2008-04-17 Supergen, Inc. Quinoline derivatives for modulating dna methylation
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
US7939546B2 (en) * 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7790746B2 (en) * 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
US9707278B2 (en) * 2014-04-17 2017-07-18 Augusta University Research Institute, Inc. Methods of modulating immune responses by modifying Akt3 bioactivity
US10292978B2 (en) * 2016-01-15 2019-05-21 Augusta University Research Institute, Inc. Specific Akt3 inhibitor and uses thereof
US10342868B2 (en) * 2016-01-15 2019-07-09 Augusta University Research Institute, Inc. Methods and compositions for inhibiting Akt3
CN110366749A (zh) * 2017-06-29 2019-10-22 惠普发展公司，有限责任合伙企业 可操作来具有充当主显示器的区域和充当辅显示器的区域的连续平面显示器
MX2020002611A (es) * 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.

Also Published As

Publication number Publication date
CA3182675A1 (en) 2021-11-11
WO2021226510A9 (en) 2022-01-13
BR112022022327A2 (pt) 2023-01-03
WO2021226510A3 (en) 2021-12-16
JP2023525758A (ja) 2023-06-19
MX2022014019A (es) 2023-02-16
US20230181563A1 (en) 2023-06-15
AU2021269065A1 (en) 2022-12-15
CN115956078A (zh) 2023-04-11
KR20230019109A (ko) 2023-02-07
EP4146196A4 (en) 2024-06-26
EP4146196A2 (en) 2023-03-15
PH12022553026A1 (en) 2024-05-13
WO2021226510A2 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
KR102917509B1 (ko) 특이적 akt3 활성제 및 이의 용도
Fang et al. In situ polymerization of zwitterions on therapeutic proteins to enable their effective oral delivery
CN105164143B (zh) 用于将分子引入到乳糜微粒中的胆固醇体囊泡
WO2018057825A1 (en) Antigen-specific immune modulation
IL292567A (en) Peptide conjugated particles
US20220016256A1 (en) Methods, device and reagents to treat allergy and autoimmune disease
RS60181B1 (sr) Terapeutska upotreba morfogenetskih proteina kosti
US20220280557A1 (en) Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders
IL297596A (en) Modulators of akt3 and methods of using them
Wu et al. Biomimetic “trojan horse” fibers modulate innate immunity cascades for nerve regeneration
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
JP2003231698A (ja) 自己免疫性を改善せしめるうえで有用なｍｈｃコンジュゲート
CN115552013A (zh) 修饰的微核小体核心蛋白及其在核酸递送中的用途
JP2019534300A (ja) プログラム細胞死リガンド１の腸管発現
Zhang et al. Intranasal delivery of hydrophobic AC5216 loaded nanoemulsion into brain to alleviate chronic unpredictable stress-induced depressive-like behaviors
JP7630540B2 (ja) 神経保護ペプチド
CA2750005C (fr) Polypeptides d'adressage specifique a des cellules-cibles d'otx2
HK40084846A (en) Akt3 modulators and methods of use thereof
Gu et al. Dual Pro‐Angiogenic and Pro‐Fibrotic MARCO+ Microglial Phenotype in Diabetic Retinopathy
Kakunuri a proliferation inducing ligand as a neuroregenerative treatment in multiple sclerosis
US20190008900A1 (en) Methods and reagents to treat autoimmune diseases and allergy
RU2815372C2 (ru) Специфический активатор akt3 и его применение
Xie Engineering T Cell Trafficking and Function for Enhanced Cancer Immunotherapy
WO2025207562A1 (en) Delivery of ccl22 muteins for the selective attraction of ccr4-receptor engineered immune cells
WO2023197014A2 (en) Combination therapy comprising pd-l1 knockout nk cell and anti-pdl1 antibodies